FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): May 15, 2019
|
SECOND SIGHT MEDICAL PRODUCTS, INC. |
|||||
|
(Exact Name of Registrant as Specified in Its Charter) |
|||||
|
|
|||||
|
California |
|||||
|
(State or Other Jurisdiction of Incorporation) |
|||||
|
|
|||||
|
|
001-36747 |
|
|
02-0692322 |
|
|
|
(Commission File Number) |
|
|
(IRS Employer Identification No.) |
|
|
|
|
||||
|
|
|
||||
|
12744 San Fernando Road, Suite 400 |
|||||
|
(Address of Principal Executive Offices) |
|||||
|
|
|||||
|
(818) 833-5000 |
|||||
|
(Registrant's Telephone Number, Including Area Code) |
|||||
|
|
|||||
|
|
|||||
|
(Former Name or Former Address, if Changed Since Last Report) |
|||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
Common Stock |
|
EYES |
|
NASDAQ |
|
Warrants |
|
EYESW |
|
NASDAQ |
ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On May 15, 2019, Second Sight Medical Products, Inc. (the “Company”) announced financial results for the three-month period ended March 31, 2019, in the earnings release attached hereto as Exhibit 99.1.
The information in this Item 2.02 including Exhibit 99.1 hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS
|
Exhibit No. |
|
Description |
|
|
|
|
|
99.1 |
|
Earnings Release of Second Sight Medical Products, Inc. dated May 15, 2019 |
|
|
|
|
|
|
|
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 15, 2019
SECOND SIGHT MEDICAL PRODUCTS, INC.
|
/s/ John T. Blake |
|
|
By: John T. Blake |
|
|
Chief Financial Officer |
|